AZD4547 has been used in clinical trials of gastric adenocarcinoma [30], and Erdafitinib (BalversaTM, Janssen Pharmaceutical Companies) [31] and BGJ398 (Infigratinib) [27, 32] was or will be approved by FDA for treatment of tumor with FGFR2 alterations. This evidence concerns the gene FGFR2 and neoplasm.